



Published Articles, Reports, and Reviews

Grant Period: 2000 - 2001

(Original Publications, Reports, and Reviews acknowledging Fondation Leducq support)

1. Libby P, Aikawa M, Schönbeck U. Cholesterol and atherosclerosis. *Biochim Biophys Acta* 2000;1529:299-309. (Invited contribution to the Festschrift honoring Konrad Bloch, Nobel laureate).
2. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E for the Cholesterol and Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor and increased risk of recurrent coronary events following myocardial infarction. *Circulation* 2000; 101:2149-2153.
3. DeLemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. *J Am Coll Cardiol* 2000; 36:423-426.
4. Herman MP, Sukhova GK, Foster D, Kisiel W, Kehry M, Libby P, Schönbeck U. Tissue factor pathway inhibitor-2: A novel inhibitor of active MMPs with implications for atherosclerosis. *J Clin Invest* 2001;107:1117-1126.
5. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. *Clin Chem* 2001; 47:28-30.
6. Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. *JACC* 2001; 37:215-218.
7. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. *Circulation* 2001; 103:491-495.

8. Zee RYL, Lindpaintner K, Struk B, Hennekens CH, Ridker PM. A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. *Atherosclerosis* 2001; 154:699-702.
9. Ridker PM, Stampfer MJ, Rifai M. Novel risk factors for systematic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA* 2001; 285:2481-2485.
10. Blake G, Lindpaintner K, Schmitz C, Ridker PM. Mutation in the B-fibrinogen gene and the risk of future myocardial infarction, stroke, and venous thrombosis. *Eur Heart J* 2001; 154:1-6.

Grant Period: 2001 - 2002

(Original Publications, Reports, and Reviews acknowledging Fondation Leducq support)

11. Robbie L, Libby P. Inflammation and atherothrombosis. Saratoga Conference 2001. *Ann N Y Acad Sci* 2001;947:167-180.
12. Horton DB, Libby P, Schönbeck U. Ligation of CD40 on vascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity. *Ann N Y Acad Sci* 2001;947:329-336.
13. Libby P, Schönbeck U. CD40 signaling and plaque instability. Review. *Circ Res* 2001;89:1092-1103.
14. Zee RYL, Lunze K, Lindpaintner K, Ridker PM. A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. *Thromb Haemost* 2001;86:1141-1143.
15. Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, Ridker PM. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. *Atherosclerosis* 2002;161:469-474.
16. Ridker PM, Danesh J, Youngman L, Collins R, Stampfer MJ, Peto R, Hennekens CH. A prospective study of *Helicobacter pylori* seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. *Ann Intern Med.* 2001;135:184-188.

17. Zee RYL, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. *Atherosclerosis* 2002;163:217-219.
18. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, Breitbart R, Chung M, Schönbeck U. Expression of neutrophil collagenase (MMP-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. *Circulation* 2001;104:1899-1904.
19. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. *Circulation* 2001;104:2525-2532.
20. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone marrow cells are a source of donor intimal smooth muscle-like cells in murine transplant arteriopathy. *Nature Med* 2001;7:738-741.
21. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. *Hypertension* 2001;38:399-403.
22. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, for the Airforce/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for targeting statin therapy in the primary prevention of acute coronary events *N Engl J Med* 2001;344:26:1959-1965.
23. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Review. *Circulation* 2001;104:365-372.
24. Libby P, Schönbeck U. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix. *Circ Res.* 2001;89:195-197.
25. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. *Circ Res* 2001;89:763-771.
26. Plutzky J, Marx N, Libby P. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? Review. *J Cardiovasc Risk* 2001;8:203-210.

27. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. *Clin Chem* 2001; 47:426-430.
28. Ridker PM, Stampfer MJ, Rifai M. Novel risk factors for systematic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA* 2001; 285:2481-2485.
29. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and the risk of developing type 2 diabetes mellitus *JAMA* 2001; 286:327-334.
30. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. *Circulation* 2001;104:2266-2268.
31. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and the risk of developing type 2 diabetes mellitus *JAMA* 2001; 286:327-334.
32. Albert MA, Rifai N, Ridker PM. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. *Vasc Med* 2001;6:145-149.
33. Mach F, Libby P, Michetti P. Helicobacter pylori infection does not influence atherogenesis in vivo in mice. *Circ Res* 2002;90:e1-e4.
34. Blake GJ, Schmitz C, Lindpaintner K, Ridker PM. Mutation in the promoter region of the B-fibrinogen gene and the risk of future myocardial infarction, stroke, and venous thrombosis. *Eur Heart J* 2001; 22:2262-2266.
35. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective study of lipoprotein-associated phospholipase A2 and the risk of future cardiovascular events in women. *J Amer Coll Cardiol* 2001; 38:1302-6.
36. Gerdes N, Sukhova GK, Libby P, Young JL, Schönbeck U. Expression of interleukin 18 and IL-18 receptor on endothelial cells, smooth muscle cells and macrophages: Potential implications in atherogenesis. *J Exp Med* 2002;195:245-257.
37. Bermudez EA, Ridker PM. C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. *Prev Cardiol* 2002;5:42-46.

38. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Black S, Libby P, Mitchell PG, Lee RT. Selective matrix metalloproteinase inhibition reduces LV remodeling but does not inhibit angiogenesis following myocardial infarction. *Circulation* 2002; 105:753-758.
39. Blake GJ, Ridker PM. Tumor necrosis factor-(, inflammatory biomarkers, and atherogenesis. *Eur Heart J* 2002;23:345-347.
40. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? *Ann Intern Med* 2002; 136:529-533.
41. Ridker PM, Shih J, Cook T, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM for the AFCAPS/TexCAPS Investigators. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. *Circulation* 2002; 105:1776-1779.
42. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. *Circulation* 2002;105:2-4.
43. Libby P, Maseri A, Ridker PM. Inflammation and atherosclerosis. Review. *Circulation* 2002; 105:1135-1143.
44. Libby P, Aikawa M. Vitamin C, collagen, and cracks in the plaque. Editorial. *Circulation* 2002;105:1396-1398.
45. Zee RYL, Bates D, Ridker PM. A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of stroke. *Stroke* 2002;33:892-895.
46. Marx N, Kehrlé MS, Kohlhammer MS, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implication for atherosclerosis and transplantation-associated arteriosclerosis. *Circ Res* 2002;90:703-710.
47. Zee YLR, Bates D, Ridker PM. A prospective evaluation of the heat shock protein 70 gene polymorphisms and the risk of stroke. *Thromb Haemost* 2002; 87:622-625.
48. Furukawa Y, Libby P, Stinn JL, Becker G, Mitchell RN. Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. *Am J Pathol* 2002;160:1077-1087.
49. Beckman JA, Craeger MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA* 2002;287:2570-2581.

Grant Period: 2002 - 2003

(Original Publications, Reports, and Reviews acknowledging Fondation Leducq support)

50. Sakash JB, Rubin B, Byrne G, Lichtman A, Libby P. Cytokines induce indoleamine 2,3 dioxygenase expression in human atheroma associated cells: implications for persistent *Chlamydia pneumoniae* infection. *Infect Immun* 2002;70:359-361.
51. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schönbeck U. Induction of tissue factor expression in human endothelial cells by CD40-ligand is mediated activator protein 1, nuclear factor (B, and Egr-1. *J Biol Chem* 2002;277:25032-25039.
52. Schönbeck U, Sukhova GK, Gerdes N, Libby P. TH2 predominant immune responses prevail in human abdominal aortic aneurysm. *Am J Pathol* 2002;161:499-506.
53. Hansson G, Libby P, Schönbeck U, Yan Z-Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Review. *Circ Res* 2002;91:281-291.
54. Schönbeck U, Libby P. Matrix metalloproteinases and their inhibitors. In: Fuster V, editor. *Assessing and modifying the vulnerable atherosclerotic plaque*. Armonk, NY: Futura Publishing Company, Inc.:2002. p.335-345.
55. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. *Arterioscler Thromb Vasc Biol* 2002;22:1452-1458.
56. Geng JY-J, Libby P. Progression of atheroma: a struggle between death and procreation. *Arterioscler Thromb Vasc Biol* 2002;22:1370-1380.
57. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. *Circulation* 2002;106:1390-1396.
58. Maron R, Sukhova GK, Faria AM, Hoffman E, Mach F, Libby P, Weiner HL. Mucosal administration of HSP-65 decreases atherosclerosis and inflammation in the aortic arch of low density lipoprotein receptor-deficient mice. *Circulation* 2002;106:1708-1715.
59. Young JL, Libby P, Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. *Thromb Haemost* 2002;88:554-567.

60. Libby P, Maseri A, Ridker PM. Letter to the Editor (Shore response). *Circulation* 2002; 106:E135-E136.
61. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Review. *Nat Med* 2002;8:1257-1262.
62. Takayama K, García-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr., Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. *J Biol Chem* 2002;277:44147-44154.
63. Plutzky J, Libby P. Diabetic macrovascular disease: the glucose paradox. RAGE editorial. *Circulation* 2002;106:2760-2763.
64. Schönbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bandeviek U, Robbie L, Ganz P, Kinlay S, Libby P. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. *Circulation* 2002;106:2888-2893.
65. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schönbeck U, Blake MA, Gerhard M, Ridker PM, Libby P, Lee RT. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study using high-resolution MRI. *Arterioscler Thromb Vasc Biol* 2003;23:e11-e14.
66. Libby P. Vascular biology of atherosclerosis: overview and state of the art. In: Franciosa JA, Alexander RW, editors. A symposium: biology of atherosclerosis and its implications for treatment strategies. *Am J Cardiol* 2003;91:3A-6A.
67. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. *Am J Cardiol* 2003;91:4B-8B.
68. Libby P, Zhao DX-M. Allograft arteriosclerosis and immune-driven angiogenesis. Editorial. *Circulation* 2003;107:1237-1239.
69. Sukhova GK, Zhang Y, Pan J-H, Wada Y, Yamamoto T, Naito M, Kodama T, Libby P, Shi G-P. Deficiency of Cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. *J Clin Invest* 2003;111:897-906.